WO2000025775A1 - Water-miscible pharmaceutical compositions of paclitaxel - Google Patents
Water-miscible pharmaceutical compositions of paclitaxel Download PDFInfo
- Publication number
- WO2000025775A1 WO2000025775A1 PCT/US1999/021990 US9921990W WO0025775A1 WO 2000025775 A1 WO2000025775 A1 WO 2000025775A1 US 9921990 W US9921990 W US 9921990W WO 0025775 A1 WO0025775 A1 WO 0025775A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- pharmaceutically
- paclitaxel
- acceptable
- miscible
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- compositions that may be used as pharmaceutical compositions, methods and kits, more particularly to improved pharmaceutical compositions, methods and kits including paclitaxel and pharmaceutically-acceptable, water-miscible, non-aqueous solvents.
- Paclitaxel is a unique diterpene anticancer compound derived from the bark of the Taxus brevifolla (Pacific yew) tree. A crude extract of the bark demonstrated antineoplastic activity in preclinical tumor screening 30 years ago as part of the National Cancer Institute's (NCI's) large-scale screening program. The active component of the extract, paclitaxel, was isolated and described by M. C. Wani et al, Plant antitumor agents. VI: The isolation and structure of
- Paclitaxel a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93:2325-2327 (1971). This document, and all others referred to herein, are incorporated by reference as if reproduced fully below.
- Paclitaxel stabilizes the tubulin polymer and promotes microtubule assembly, rather than inducing microtubule disassembly like the antimicrotubule agents colchicine, vincristine, and vinblastine. This stabilization results in the inhibition of the normal dynamic reorganization of the microtubule network. Encouraging response rates (complete and partial) have been reported in single-agent phase II studies of paclitaxel in breast cancer, previously untreated non-small-cell lung cancer, head and neck cancer, and refractory ovarian cancer.
- paclitaxel is poorly soluble in water (less than 0.01 mg/mL) and other common vehicles used for the parenteral administration of drugs. Certain organic solvents, however, may at least partially dissolve paclitaxel. However, when a water-miscible organic solvent containing paclitaxel at near its saturation solubility is diluted with water, the drug may precipitate.
- Each milliliter of formulation contains approximately 6 mg Paclitaxel, 527 mg of Cremophor EL, and 49.7% (vol/vol) dehydrated alcohol. This concentrated formulation must be further diluted with NS, D5W, D5NS, or D5 W-R prior to administration. Additional information regarding Cremophor formulations of paclitaxel may be found in Agharkar et al., U.S. Patent No. 5,504,102.
- paclitaxel was administered after premedication with steroids (such as dexamethasone), antihistamines (such as diphenhydramine), and H2-antagonists (such as cimetidine or ranitidine), and the infusion time was extended to 24 hours in an attempt to eliminate the most serious allergic reactions.
- steroids such as dexamethasone
- antihistamines such as diphenhydramine
- H2-antagonists such as cimetidine or ranitidine
- Polyvinylchloride (PVC) infusion bags and intravenous administration sets usually contain diethylhexylphthalate (DEHP) as a plasticizer to maximize component flexibility.
- DEHP diethylhexylphthalate
- Exposure of animals to chronic high doses (more than 100 mg/kg) of DEHP has resulted in toxic effects including growth retardation, liver weight increase, liver damage, testicular atrophy, teratogenicity, and carcinogenicity.
- Cosolvents and surfactants may increase the amount of plasticizer leached.
- the invention relates to a composition
- a composition comprising: paclitaxel; and a pharmaceutically-acceptable, water-miscible, non-aqueous solvent; wherein the composition is suitable for administration to a host in need thereof, and wherein the composition has a concentration of paclitaxel greater than or equal to about 1.5 mg/mL, a viscosity less than or equal to about 3.0 cp, as determined by the pipette/capillary method, and is substantially stable for four weeks at 50° C; and wherein the pharmaceutically-acceptable, water-miscible, non-aqueous solvent has an average LD50, when administered intravenously to a mouse, of greater than or equal to about 2.0 mL/kg.
- the invention in another aspect, relates to a composition made by the acts comprising providing paclitaxel; combining the paclitaxel with a pharmaceutically-acceptable, water-miscible, non-aqueous solvent; wherein the composition is suitable for administration to a host in need thereof, and wherein the composition has a concentration of paclitaxel greater than or equal to about 1.5 mg/mL, a viscosity less than or equal to about 3.0 cp, as determined by the pipette/capillary method, and is substantially stable for four weeks at fifty degrees Celsius; and wherein the pharmaceutically-acceptable, water-miscible, non-aqueous solvent has an average LD50, when administered intravenously to a mouse, of greater than or equal to about 2.0 mL/kg.
- the invention in another aspect, relates to a composition
- a composition comprising: paclitaxel; and a pharmaceutically-acceptable, water-miscible, non-aqueous solvent; wherein the composition is substantially ethanol-free.
- the invention relates to a composition made by the acts comprising: providing paclitaxel; combining the paclitaxel with a pharmaceutically-acceptable, water-miscible, non-aqueous solvent; wherein the composition is substantially ethanol-free.
- the invention relates to a composition
- a composition comprising: paclitaxel; and a pharmaceutically-acceptable, water-miscible, non-aqueous solvent; wherein the pharmaceutically-acceptable, water-miscible, non-aqueous solvent comprises N-methol-2-pyrrolidone, 2-pyrrolidone, dimethyl sulfoxide, propylene glycol, benzyl alcohol, ethyl acetate, or dimethylacetamide.
- the invention in another aspect, relates to a composition made by the acts comprising: providing paclitaxel; combining the paclitaxel with a pharmaceutically-acceptable, water-miscible, non-aqueous solvent; wherein the pharmaceutically-acceptable, water-miscible, non-aqueous solvent comprises N- methol-2-pyrrolidone, 2-pyrrolidone, dimethyl sulfoxide, propylene glycol, benzyl alcohol, ethyl acetate, or dimethylacetamide.
- Figure 1 is a graph showing the effect of aqueous dilution on the viscosity of paclitaxel formulations.
- compositions comprising paclitaxel (abbreviated as "PCT" on occasion) and these solvents.
- PCT paclitaxel
- the invention relates to a composition
- a composition comprising: paclitaxel; and a pharmaceutically-acceptable, water-miscible, non-aqueous solvent; wherein the composition is suitable for administration to a host in need thereof, and wherein the composition has a concentration of paclitaxel greater than or equal to about 1.5 mg/mL, a viscosity less than or equal to about 3.0 cp, as determined by the pipette/capillary method, and is substantially stable for four weeks at 50° C; and wherein the pharmaceutically-acceptable, water-miscible, non-aqueous solvent has an average LD50, when administered intravenously to a mouse, of greater than or equal to about 2.0 mL/kg.
- the invention relates to the composition, wherein the pharmaceutically-acceptable, water-miscible, non-aqueous solvent comprises N- methyl pyrrolidone.
- the invention relates to the composition, further comprising a pharmaceutically-acceptable solubilizer.
- the invention relates to the composition, wherein the pharmaceutically-acceptable solubilizer comprises triacetin or polyethoxylated 12-hydroxy stearic acid.
- the invention relates to the composition, with the proviso that pharmaceutically-acceptable solubilizers are excluded from the composition.
- the invention relates to the composition, with the proviso that polyoxyethylated castor oil is excluded from the composition.
- the invention relates to a composition made by the acts comprising providing paclitaxel; combining the paclitaxel with a pharmaceutically-acceptable, water-miscible, non-aqueous solvent; wherein the composition is suitable for administration to a host in need thereof, and wherein the composition has a concentration of paclitaxel greater than or equal to about 1.5 mg/mL, a viscosity less than or equal to about 3.0 cp, as determined by the pipette/capillary method, and is substantially stable for four weeks at 50° C; and wherein the pharmaceutically-acceptable, water-miscible, non-aqueous solvent has an average LD50, when administered intravenously to a mouse, of greater than or equal to about 2.0 mL/kg.
- the invention relates to a method of administering paclitaxel to a host in need thereof comprising: providing a composition as disclosed herein; and administering the composition to a host in need thereof.
- the invention relates to kits comprising the composition disclosed herein in a pharmaceutically acceptable dosage form.
- the invention relates to a composition
- a composition comprising paclitaxel; and a pharmaceutically-acceptable, water-miscible, non-aqueous solvent; wherein the composition is substantially ethanol-free.
- the invention relates to the composition, wherein the pharmaceutically- acceptable, water-miscible, non-aqueous solvent comprises N-methyl pyrrolidone, propylene glycol, ethyl acetate, dimethyl sulfoxide, dimethyl acetamide, benzyl alcohol, 2-pyrrolidone, or benzyl benzoate.
- the invention relates to the composition, wherein the pharmaceutically- acceptable, water-miscible, non-aqueous solvent comprises N-methyl pyrrolidone. In still another aspect, the invention relates to the composition, further comprising a pharmaceutically-acceptable solubilizer. In another aspect, the invention relates to the composition, wherein the pharmaceutically- acceptable solubilizer comprises triacetin or polyethoxylated 12-hydroxy stearic acid. In yet another aspect, the invention relates to the composition, with the proviso that pharmaceutically-acceptable solubilizers are excluded from the composition. In a further aspect, the invention relates to the composition, with the proviso that polyoxyethylated castor oil is excluded from the composition.
- the invention relates to a composition made by the acts comprising providing paclitaxel; combining the paclitaxel with a pharmaceutically-acceptable, water-miscible, non-aqueous solvent; wherein the composition is substantially ethanol-free.
- the invention relates to a method of administering paclitaxel to a host in need thereof comprising providing the composition disclosed herein; and administering that composition to a host in need thereof.
- the invention relates to a kit comprising the composition disclosed herein in a pharmaceutically acceptable dosage form.
- the invention relates to a composition
- a composition comprising paclitaxel; and a pharmaceutically-acceptable, water-miscible, non-aqueous solvent; wherein the composition is substantially ethanol-free.
- the invention relates to the composition, wherein the pharmaceutically- acceptable, water-miscible, non-aqueous solvent comprises N-methyl pyrrolidone, propylene glycol, ethyl acetate, dimethyl sulfoxide, dimethyl acetamide, benzyl alcohol, 2-pyrrolidone, or benzyl benzoate.
- the invention relates to the composition, wherein the pharmaceutically- acceptable, water-miscible, non-aqueous solvent comprises N-methyl pyrrolidone. In still another aspect, the invention relates to the composition, further comprising a pharmaceutically-acceptable solubilizer. In another aspect, the invention relates to the composition, wherein the pharmaceutically- acceptable solubilizer comprises triacetin or polyethoxylated 12-hydroxy stearic acid. In yet another aspect, the invention relates to the composition, with the proviso that pharmaceutically-acceptable solubilizers are excluded from the composition. In a further aspect, the invention relates to the composition, with the proviso that polyoxyethylated castor oil is excluded from the composition.
- the invention relates to a composition made by the acts comprising: providing paclitaxel; combining the paclitaxel with a pharmaceutically-acceptable, water-miscible, non-aqueous solvent; wherein the pharmaceutically-acceptable, water-miscible, non-aqueous solvent comprises N- methol-2 -pyrrolidone, 2-pyrrolidone, dimethyl sulfoxide, propylene glycol, benzyl alcohol, ethyl acetate, or dimethylacetamide.
- the invention relates to a method of administering paclitaxel to a host in need thereof comprising: providing the composition disclosed herein; and administering the composition to a host in need thereof.
- the invention relates to a kit comprising the composition in a pharmaceutically acceptable dosage form.
- Pharmaceutical grade paclitaxel suitable for use in this invention may be obtained from a variety of sources, including the National Cancer Institute (Bethesda, MD).
- paclitaxel may be taken to mean paclitaxel proper, and paclitaxel derivatives, analogs, and prodrugs thereof.
- Solvents usable in the practice of this invention include pharmaceutically- acceptable, water-miscible, non-aqueous solvents.
- these solvents should be taken to include solvents that are generally acceptable for pharmaceutical use, substantially water-miscible, and substantially non-aqueous.
- these solvents are also non-phthalate plasticizer leaching solvents, so that, when used in medical equipment, they substantially do not leach phthalate plasticizers that may be present in the medical equipment.
- the pharmaceutically-acceptable, water-miscible, non-aqueous solvents usable in the practice of this invention include, but are not limited to, N- methyl pyrrolidone (NMP); propylene glycol; ethyl acetate; dimethyl sulfoxide; dimethyl acetamide; benzyl alcohol; 2-pyrrolidone; benzyl benzoate; C 2 ⁇ alkanols; 2-ethoxyethanol; alkyl esters such as 2-ethoxyethyl acetate, methyl acetate, ethyl acetate, ethylene glycol diethyl ether, or ethylene glycol dimethyl ether; (s)-(-)-ethyl lactate; acetone; glycerol; alkyl ketones such as methylethyl ketone or dimethyl sulfone; tetrahydrofuran; cyclic alkyl amides such as caprolactam; decylene glycol
- the most preferred pharmaceutically-acceptable, water-miscible, non- aqueous solvents comprise N-methyl pyrrolidone (NMP), propylene glycol, ethyl acetate, dimethyl sulfoxide, dimethyl acetamide, benzyl alcohol, 2-pyrrolidone, or benzyl benzoate.
- NMP N-methyl pyrrolidone
- propylene glycol propylene glycol
- ethyl acetate dimethyl sulfoxide
- dimethyl acetamide dimethyl acetamide
- benzyl alcohol 2-pyrrolidone
- 2-pyrrolidone or benzyl benzoate.
- Ethanol may also be used as a pharmaceutically-acceptable, water-miscible, non-aqueous solvent according to the invention, despite its negative impact on stability.
- triacetin may also be used as a pharmaceutically-acceptable, water-miscible, non-aqueous solvent,
- NMP may be available as Pharmasolve® from International Specialty Products (Wayne, NJ).
- Benzyl alcohol may be available from J. T. Baker, Inc.
- Ethanol may be available from Spectrum, Inc.
- Triacetin may be available from Mallinkrodt, Inc.
- Solubilizers may also be used in the practice of this invention. Solubilization is a phenomenon that enables the formation of a solution. It is related to the presence of amphiphiles — those molecules that have the dual properties of being both polar and non-polar — in the solution that have the ability to increase the solubility of materials that are normally insoluble or only slightly soluble, in the dispersion medium. Solubilizers often have surfactant properties. Their function may be to enhance the solubility of a solute in a solution, rather than acting as a solvent, although in exceptional circumstances, a single compound may have both solubilizing and solvent characteristics.
- Solubilizers useful in the practice of this invention include, but are not limited to, triacetin, polyethylene glycols (such as PEG 300, PEG 400, or their blend with 3350), polysorbates (such as Polysorbate 20, Polysorbate 40, Polysorbate 60, Polysorbate 65, or Polysorbate 80), poloxamers (such as Poloxamer 124,
- compositions include cyclodextrins, and cyclodextrin analogs and derivatives, and other soluble excipients that could enhance the stability of the inventive composition, maintain the product in solution, or prevent side effects associated with the administration of the inventive composition.
- Cyclodextrins may be available as Encapsin® from
- inventive compositions may be prepared by dissolving paclitaxel in a small quantity of the pharmaceutically-acceptable, water-miscible, non-aqueous solvent with moderate agitation. The volume of the inventive composition is then made up with the remaining solvent and ingredients and mixed thoroughly.
- the excipients such as hydroxypropyl cyclodextrin
- the excipients may be dissolved in an aliquot of the pharmaceutically-acceptable, water-miscible, non-aqueous solvent. This aliquot may then be mixed with a premixed solution of paclitaxel and pharmaceutically-acceptable, water-miscible, non-aqueous solvent as described above. The mixed aliquots are then mixed together, and the remaining volume is made up, all under moderate agitation.
- the inventive compositions may contain varying amounts of each of the paclitaxel, the pharmaceutically-acceptable, water-miscible, non-aqueous solvent, and other ingredients.
- the inventive compositions comprise paclitaxel in an amount ranging from about 0.001 to about 1% w/v, more preferably from about 0.01 to about 0.8%w/v.
- the composition comprises paclitaxel in an amount greater than or equal to about 1.5 mg/ml, more preferably in an amount greater than or equal to about 2.5 mg/ml.
- the inventive compositions comprise the pharmaceutically-acceptable, water-miscible, non- aqueous solvent in an amount ranging from about 25%w/v to about 99.999% w/v, more preferably from about 50 to about 99.99% w/v, and still more preferably from about 75 to about 99% w/v.
- the inventive compositions comprise a solubilizer in an amount ranging from about 0.001 to about 50% w/v, more preferably from about 0.01 to about 30% w/v.
- the ratio of w/v in this context refers to the weight of the material divided by the total volume of the solution or formulation.
- inventive compositions may be used in the treatment of a variety of cancers, including, but not limited to ovarian carcinoma, breast carcinoma, lung carcinoma and Kaposi's sarcoma.
- compositions according to the invention may be administered in any medically suitable manner, preferably parenterally or orally, more preferably parenterally, and still more preferably intravenously.
- the compositions may be diluted with sterile water, normal saline, D5W, Ringer's solution or other equivalent infusion liquids. Preferable dilutions range from about 5: 1 to about
- the dilution ranges from about 2: 1 to 1 :2. Most preferably, the dilution may be 1 :1.
- the ratio of v/v in this context refers to the ratio of the volume of the composition before dilution with the infusion fluids to the total volume of the composition following dilution with the infusion fluid.
- inventive compositions may be administered in a bolus fashion.
- a therapeutic dose of paclitaxel ranges from about 135 to about 175 mg/m 2 of paclitaxel. This dosage may be administered over a range of time from approximately thirty minutes to approximately 24 hours.
- An advantage of this invention is that relatively little dilution with infusion fluids may need to be made as part of the administration procedure, although larger dilution volumes may be contemplated as within the scope of the invention
- Conventional pre-medication optionally may be performed before administering the inventive compositions to a patient, to reduce the chance of hypersensitivity reactions. Additionally, desensitization procedures optionally may be performed.
- the inventive compositions are substantially ethanol- free, although various other embodiments of the invention comprise compositions that comprise ethanol. Preferable inventive compositions that are substantially ethanol-free surprisingly and unexpectedly exhibit superior chemical stability of paclitaxel compared to compositions that are not substantially ethanol-free.
- Chemical stability generally refers to the amount of chemical degradation of a particular material. Obviously, when administering materials such as paclitaxels, a highly stable formulation is desirable. Chemical stability of a pharmaceutical preparation depends upon the amount of chemical degradation of the active pharmaceutical ingredient in that preparation. Commonly, stability analysis of a pharmaceutical preparation, such as a liquid parenteral product, may be performed under accelerated temperature conditions, such as in a 50° C oven. The kinetic methods used in the accelerated stability analysis need not involve detailed studies of mechanism of degradation to be able to predict stability, but they are preferably based upon sound scientific principles and compliance with regulatory requirements.
- Developing formulations of acceptable chemical stability may be important, especially in cases where the composition comprises a cytotoxic drug like the paclitaxels. Physicians will find undesirable those products for which they must determine the exact amount of paclitaxel present before using the products. Additionally, regulatory requirements may specify minimum stability requirements. Therefore, discovery of variables that impact stability is a useful step in development of new pharmaceutical formulations. The inventors do not wish to be bound by a particular explanation of the mechanism by which ethanol may be responsible for degradation of paclitaxel, as such explanation is not necessary to practice the invention. It may be, however, helpful to consider some hypothetical mechanisms for possible reasons for paclitaxel degradation in the presence of ethanol.
- Those pharmaceutical agents that have an ester linkage such as paclitaxel, can be cleaved by an alcohol, specifically ethanol.
- the presence of ethanol therefore may serve to increase the rate of degradation of paclitaxel with concomitant reduction in stability.
- the chemical stability of paclitaxel in a 50° C oven over four weeks is greater than about 85%. In a more preferred embodiment, the chemical stability of paclitaxel in a 50° C oven over four weeks is greater than about 90%. In a still more preferred embodiment, the chemical stability of paclitaxel in a 50° C oven over four weeks is greater than about 93%. In a most preferred embodiment, the chemical stability of paclitaxel in a 50° C oven over four weeks is greater than about 96%.
- vehicle toxicity Another interesting factor in pharmaceutical formulation development is vehicle toxicity. While varying amounts of toxicity are acceptable, especially in cytotoxic formulations, it is nevertheless desirable to reduce vehicle toxicity whenever practical.
- One surrogate measurement for vehicle toxicity is the LD50 ⁇ the dosage at which 50% of the test subject die from being administered the vehicle.
- Common models for LD50 include well-accepted animal models such as the mouse.
- Mouse intravenous LD50 values can serve to quantify the levels of vehicle toxicity between different vehicles, and serve a useful role in selecting appropriate vehicles for pharmaceutical formulation development.
- the pharmaceutically-acceptable, water-miscible, non-aqueous solvents according to the invention have an intravenous LD50 in mice of greater than or equal to about 0.5 ml/kg, more preferably greater than or equal to about 1.5 ml/kg, still more preferably greater than or equal to about 2.0 ml/kg, and most preferably greater than or equal to about 2.5 ml/kg.
- inventive compositions are of relatively low viscosities, even at high paclitaxel concentrations. This is in contrast to Taxol®, which is of relatively high viscosity at high paclitaxel concentrations.
- the viscosity of paclitaxel-containing formulation was investigated as follows. The viscosity of a Newtonian liquid may be determined by measuring the time required for the liquid to pass between two marks as it flows by gravity through a vertical capillary tube. The time of flow of liquid under the test is compared with the time required for a liquid of known viscosity (usually water) to pass between the two marks.
- the equation is based on the Poiseuille's law for a liquid flowing through a capillary tube
- r radius of the capillary
- t time of flow
- ⁇ R pressure head in dynes/cm 2 under which the liquid flows
- . length of the capillary
- K the volume of liquid flowing.
- the radius, length and the volume of the capillary are invariants and may be combined into a constant K.
- Viscosities may be measured using the pipette/capillary method.
- the time of flow for lmL of a particular formulation or liquid with unknown viscosity may be measured with a stopwatch using a standard volumetric pipette of constant length, diameter, and volume, such as a lmL volumetric pipette. This time of
- flow may be compared against the time of flow for a liquid of known viscosity to arrive at a viscosity determination for the unknown liquid.
- Another interesting aspect of the invention relates to the effect of dilution on the clarity of various paclitaxel containing formulations.
- PDR Physician's Desk Reference
- Taxol® involves dilution prior to infusion. Taxol® may be diluted in 0.9%
- Sodium Chloride for Injection USP 5% Dextrose for Injection USP, 5% Dextrose and 0.9% Sodium Chloride for Injection USP, or 5% Dextrose in Ringer's Solution for Injection USP to a final concentration of 0.3 - 1.2 mg/ml.
- the solutions may be physically and chemically stable for up to 27 hours at room temperature and room lighting conditions.
- Taxol® or Taxol® equivalent formulations of paclitaxel containing Cremophor when diluted 1:3 or 1:4 with 0.9%) NaCl to achieve a drug concentration of 0.75 or 0.38 mg/mL, respectively, may remain clear for 24 ⁇ 3 hr. However, those diluted 1 :1 or 1 :2 with 0.9%
- inventive compositions when diluted 1:1 to achieve a concentration range of 2.5-4 mg/mL (depending on the cosolvent composition) are able to remain clear for 24 ⁇ 3 hr.
- the viscosities of these diluted formulations are comparable to the 1 :3 and 1 :4 dilutions of the earlier Cremophor containing formulations facilitating intravenous administration. Therefore, the inventive compositions may be diluted to equivalent viscosities of diluted, conventional, Taxol® or Taxol® equivalent formulations, using smaller volumes of diluting infusion fluids.
- the diluted inventive formulations may have acceptable physical stability for up to 24 hours.
- This recombined mixture was then tested for chemical stability of paclitaxel by placing an aliquot of the mixture in a 50° C stability oven. Samples were taken at one week intervals and tested for chemical stability. The stability testing was performed using an HPLC method. An LC-F (penta-fluorophenyl bonded phase) 5 ⁇ m, 100 A pore size, 4.6 x 250 mm column was used. A UV detector was used, and set at 227 nm. The mobile phase was made up of a 37:58:5 mixture of ACN: Water: MeOH (containing 1 mL/L of H 3 PO 4 ). The flow rate was 1.2 mL/minute. The diluent used was acidic methanol (MeOH containing 0.1% acetic acid). The sample concentration was 0.01 mg/mL. The injection volume was 20 ⁇ l. The retention time was 14.5 minutes. The results are shown in Table I below.
- Example 8 The recombined mixture was then tested for chemical stability of paclitaxel by placing an aliquot of the mixture in a 50 °C stability oven. Chemical stability of the paclitaxel was determined using the method outlined in Example 1. The results are shown in Table I below.
- Example 8 The results are shown in Table I below.
- the recombined mixture is then tested for chemical stability of paclitaxel by placing an aliquot of the mixture in a 50° C stability oven. Chemical stability of the paclitaxel is determined using the method outlined in Example 1.
- Cremophor®, ethanol and paclitaxel were tested at various dilution amounts.
- the viscosity determinations were performed according to the pipette/capillary method, discussed above, under the assumption that the formulations were Newtonian liquids.
- the time of flow for lmL of various diluted formulations with unknown viscosities was measured with a stopwatch using a standard volumetric pipette of constant length, diameter, and volume of lmL.
- time taken for water, with a known viscosity of 0.89 cp, to flow through the same tube was recorded.
- the viscosity determination was made using Poisuelle's equation: ⁇ l ⁇ l 2 ' as discussed above, wherein
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU63977/99A AU775158B2 (en) | 1998-10-30 | 1999-09-22 | Water-miscible pharmaceutical compositions of paclitaxel |
MXPA01004268A MXPA01004268A (en) | 1998-10-30 | 1999-09-22 | Water-miscible pharmaceutical compositions of paclitaxel. |
AT99951559T ATE254455T1 (en) | 1998-10-30 | 1999-09-22 | WATER-MIXABLE PHARMACEUTICAL COMPOSITIONS CONTAINING PACLITAXEL |
DE69912983T DE69912983D1 (en) | 1998-10-30 | 1999-09-22 | WATER MIXABLE PHARMACEUTICAL COMPOSITIONS CONTAINING PACLITAXEL |
EP99951559A EP1124549B1 (en) | 1998-10-30 | 1999-09-22 | Water-miscible pharmaceutical compositions of paclitaxel |
CA002345697A CA2345697A1 (en) | 1998-10-30 | 1999-09-22 | Water-miscible pharmaceutical compositions of paclitaxel |
IL14272099A IL142720A (en) | 1998-10-30 | 1999-09-22 | Water-miscible pharmaceutical compositions of paclitaxel |
JP2000579216A JP2002528494A (en) | 1998-10-30 | 1999-09-22 | Water-miscible pharmaceutical composition of paclitaxel |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/183,199 US6017948A (en) | 1998-10-30 | 1998-10-30 | Water-miscible pharmaceutical compositions |
US09/183,199 | 1998-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000025775A1 true WO2000025775A1 (en) | 2000-05-11 |
Family
ID=22671864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/021990 WO2000025775A1 (en) | 1998-10-30 | 1999-09-22 | Water-miscible pharmaceutical compositions of paclitaxel |
Country Status (11)
Country | Link |
---|---|
US (1) | US6017948A (en) |
EP (1) | EP1124549B1 (en) |
JP (1) | JP2002528494A (en) |
CN (1) | CN1178655C (en) |
AT (1) | ATE254455T1 (en) |
AU (1) | AU775158B2 (en) |
CA (1) | CA2345697A1 (en) |
DE (1) | DE69912983D1 (en) |
IL (1) | IL142720A (en) |
MX (1) | MXPA01004268A (en) |
WO (1) | WO2000025775A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010048330A1 (en) * | 2008-10-21 | 2010-04-29 | Threshold Pharmaceuticals, Inc. | Treatment of cancer using hypoxia activated prodrugs |
US9226932B2 (en) | 2005-06-29 | 2016-01-05 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6774278B1 (en) * | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
US6040330A (en) * | 1999-01-08 | 2000-03-21 | Bionumerik Pharmaceuticals, Inc. | Pharmaceutical formulations of taxanes |
US6136846A (en) * | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
US6828346B2 (en) * | 1999-10-25 | 2004-12-07 | Supergen, Inc. | Methods for administration of paclitaxel |
US6656966B2 (en) | 2000-06-22 | 2003-12-02 | Nitromed, Inc. | Nitrosated and nitrosylated taxanes, compositions and methods of use |
AU2002240755B2 (en) * | 2001-03-13 | 2007-07-05 | Angiotech International Ag | Micellar drug delivery vehicles and uses thereof |
DE10115740A1 (en) * | 2001-03-26 | 2002-10-02 | Ulrich Speck | Preparation for restenosis prophylaxis |
NZ529647A (en) | 2001-04-20 | 2007-05-31 | Univ British Columbia | Micellar drug delivery systems for hydrophobic drugs |
US20030126788A1 (en) * | 2001-11-07 | 2003-07-10 | Colloid Tech. Inc. | Storage stable translucent flammable article |
KR20050044621A (en) * | 2001-11-30 | 2005-05-12 | 브리스톨-마이어스 스큅 컴퍼니 | Paclitaxel solvates |
US6537985B1 (en) | 2001-11-30 | 2003-03-25 | Phoenix Scientific, Inc. | Antibiotic formulation and a method of making this formulation |
AU2003247671B2 (en) * | 2002-07-15 | 2008-02-14 | Alcon, Inc. | Bioerodible film for ophthalmic drug delivery |
DE10244847A1 (en) | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medical device for drug delivery |
US9943490B2 (en) | 2007-11-05 | 2018-04-17 | The Trustees Of Princeton University | Composite flash-precipitated nanoparticles |
CA2710525C (en) * | 2007-12-24 | 2017-08-22 | Sun Pharma Advanced Research Company Limited | Nanodispersion |
CN102802624A (en) | 2009-06-19 | 2012-11-28 | 太阳医药高级研发有限公司 | Nanodispersion Of A Drug And Process For Its Preparation |
NZ603828A (en) | 2010-05-03 | 2015-09-25 | Teikoku Pharma Usa Inc | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
US20120172796A1 (en) | 2010-12-30 | 2012-07-05 | Chappa Ralph A | Composition for intravascular delivery of therapeutic composition |
JO3685B1 (en) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | Non-aqueous taxane nanodispersion formulations and methods of using the same |
CN112972419B (en) * | 2019-12-02 | 2024-03-08 | 四川科伦药物研究院有限公司 | Preparation method of albumin nano-drug composition |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996029070A1 (en) * | 1995-03-17 | 1996-09-26 | The Board Of Regents, The University Of Texas System | Extended stability formulations for paclitaxel |
US5922754A (en) * | 1998-10-02 | 1999-07-13 | Abbott Laboratories | Pharmaceutical compositions containing paclitaxel |
US5965603A (en) * | 1997-07-21 | 1999-10-12 | American Cyanamid Company | Nonaqueous compositions for parenteral administration |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE74244B1 (en) * | 1985-10-01 | 1997-07-16 | Bimeda Res Dev Ltd | A process for preparing an antibiotic composition |
US5034397A (en) * | 1985-12-12 | 1991-07-23 | Bristol-Myers Squibb Co. | Stable, water soluble salt compositions of M-AMSA in 1-methyl-2-pyrrolidinone |
US4772589A (en) * | 1986-10-29 | 1988-09-20 | Bristol-Myers | Etoposide solution in NMP |
EP0473707A4 (en) * | 1989-05-26 | 1992-12-09 | Abbott Laboratories | Injectable clarithromycin composition |
US5082863A (en) * | 1990-08-29 | 1992-01-21 | Schering Corporation | Pharmaceutical composition of florfenicol |
CA2086874E (en) * | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
EP0626171A1 (en) * | 1993-05-26 | 1994-11-30 | Winfried Dörnhöfer | Oxytetracycline or doxycycline injectable solution containing PVP and N-methylpyrrolidone and/or 2-pyrrolidone |
TW406020B (en) * | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
US5858999A (en) * | 1994-09-01 | 1999-01-12 | Pharmacia & Upjohn Company | Cosolvent parenteral formulation of tirilazad |
AU4652596A (en) * | 1995-01-09 | 1996-07-31 | Atrix Laboratories, Inc. | Liquid polymer delivery system |
US5726181A (en) * | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
HU227918B1 (en) * | 1995-12-21 | 2012-06-28 | Pfizer | Injectable quinolone formulations |
US5773422A (en) * | 1996-01-29 | 1998-06-30 | Komer; Gene | Avermectin formulation |
US5877205A (en) * | 1996-06-28 | 1999-03-02 | Board Of Regents, The University Of Texas System | Parenteral paclitaxel in a stable non-toxic formulation |
-
1998
- 1998-10-30 US US09/183,199 patent/US6017948A/en not_active Expired - Fee Related
-
1999
- 1999-09-22 WO PCT/US1999/021990 patent/WO2000025775A1/en active IP Right Grant
- 1999-09-22 EP EP99951559A patent/EP1124549B1/en not_active Expired - Lifetime
- 1999-09-22 CN CNB998126624A patent/CN1178655C/en not_active Expired - Fee Related
- 1999-09-22 IL IL14272099A patent/IL142720A/en not_active IP Right Cessation
- 1999-09-22 AU AU63977/99A patent/AU775158B2/en not_active Ceased
- 1999-09-22 JP JP2000579216A patent/JP2002528494A/en active Pending
- 1999-09-22 DE DE69912983T patent/DE69912983D1/en not_active Expired - Lifetime
- 1999-09-22 MX MXPA01004268A patent/MXPA01004268A/en not_active IP Right Cessation
- 1999-09-22 CA CA002345697A patent/CA2345697A1/en not_active Abandoned
- 1999-09-22 AT AT99951559T patent/ATE254455T1/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996029070A1 (en) * | 1995-03-17 | 1996-09-26 | The Board Of Regents, The University Of Texas System | Extended stability formulations for paclitaxel |
US5965603A (en) * | 1997-07-21 | 1999-10-12 | American Cyanamid Company | Nonaqueous compositions for parenteral administration |
US5922754A (en) * | 1998-10-02 | 1999-07-13 | Abbott Laboratories | Pharmaceutical compositions containing paclitaxel |
Non-Patent Citations (2)
Title |
---|
PAHALA, SIMAMORA, ET AL.: "Emulsion Formulations for Intravenous Administration of Paclitaxel", PDA JOURNAL OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY, vol. 52, no. 4, August 1998 (1998-08-01), Philadelphia, US, pages 170 - 172, XP000874085 * |
REINECKE, P.; ET AL.: "Antiproliferative Effects of Paclitaxel (Taxol) on Human Renal Clear Cell Carcinomas In Vitro", EUROPEAN JOURNAL OF CANCER, vol. 33, no. 7, 1997, Exeter, GB, pages 1122 - 1129, XP000874028 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9226932B2 (en) | 2005-06-29 | 2016-01-05 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
WO2010048330A1 (en) * | 2008-10-21 | 2010-04-29 | Threshold Pharmaceuticals, Inc. | Treatment of cancer using hypoxia activated prodrugs |
US8946275B2 (en) | 2008-10-21 | 2015-02-03 | Threshold Pharmaceuticals, Inc. | Treatment of cancer using hypoxia activated prodrugs |
Also Published As
Publication number | Publication date |
---|---|
US6017948A (en) | 2000-01-25 |
CA2345697A1 (en) | 2000-05-11 |
AU6397799A (en) | 2000-05-22 |
AU775158B2 (en) | 2004-07-22 |
JP2002528494A (en) | 2002-09-03 |
IL142720A0 (en) | 2002-03-10 |
DE69912983D1 (en) | 2003-12-24 |
EP1124549A1 (en) | 2001-08-22 |
IL142720A (en) | 2005-03-20 |
MXPA01004268A (en) | 2002-06-04 |
CN1368880A (en) | 2002-09-11 |
ATE254455T1 (en) | 2003-12-15 |
CN1178655C (en) | 2004-12-08 |
EP1124549B1 (en) | 2003-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6017948A (en) | Water-miscible pharmaceutical compositions | |
US6319943B1 (en) | Oral formulation for paclitaxel | |
AU724842B2 (en) | Taxane composition and method | |
JP5587198B2 (en) | Freeze-dried pharmaceutical composition having improved stability, containing taxane derivative, and method for producing the same | |
EP2741745A1 (en) | Cabazitaxel formulations and methods of preparing thereof | |
JP2009509942A (en) | Fulvestrant formulation | |
EP2637655B1 (en) | Pharmaceutical composition of taxoids | |
US9763880B2 (en) | Non-aqueous taxane formulations and methods of using the same | |
US8912228B2 (en) | Docetaxel formulations with lipoic acid | |
EP2306976A2 (en) | Injectable taxane pharmaceutical composition | |
US10398785B2 (en) | Pharmaceutical compositions containing taxane-cyclodextrin complexes, method of making and methods of use | |
US20070032438A1 (en) | Pharmaceutical compositions containing taxanes and methods for preparing the pharmaceutical compositions | |
JP6292267B2 (en) | Docetaxel formulation | |
CN113456586B (en) | Docetaxel composition for injection and preparation method thereof | |
US20210015783A1 (en) | Pharmaceutical Compositions Containing Taxane-Cyclodextrin Complexes, Method of Making and Methods of Use | |
TWI246927B (en) | One kind of concentrated emulsion containing Paclitaxel (taxane) | |
JP2018115178A (en) | Docetaxel formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99812662.4 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 1999 63977 Country of ref document: AU Kind code of ref document: A |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2345697 Country of ref document: CA Ref document number: 2345697 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 63977/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 142720 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2000 579216 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/004268 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999951559 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999951559 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999951559 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 63977/99 Country of ref document: AU |